#BEGIN_DRUGCARD DB00104

# AHFS_Codes:
92:00.00

# ATC_Codes:
H01CB02

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Atrigel
Longastatin
Sandostatin
Sandostatin LAR

# CAS_Registry_Number:
83150-76-9

# ChEBI_ID:
Not Available

# Chemical_Formula:
C49H66N10O10S2

# Chemical_IUPAC_Name:
(4R,7S,10S,13R,16S,19R)-19-[(2R)-2-amino-3-phenylpropanamido]-10-(4-aminobutyl)-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2248639

# Description:
Octreotide is the acetate salt of a cyclic octapeptide. It is a long-acting octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin.

# Dosage_Forms:
Powder	Intramuscular
Solution	Intravenous

# Drug_Category:
Anabolic Agents
Antineoplastic Agents, Hormonal
Gastrointestinal Agents
Hormone Replacement Agents

# Drug_Interactions:
Artemether	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
Cyclosporine	Octreotide decreases the effect of cyclosporine
Lumefantrine	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
Quinupristin	This combination presents an increased risk of toxicity
Tacrolimus	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
Thiothixene	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
Toremifene	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
Trimipramine	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
Voriconazole	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Vorinostat	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Ziprasidone	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
Zuclopenthixol	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).

# Drug_Reference:
10207228	Uhl W, Anghelacopoulos SE, Friess H, Buchler MW: The role of octreotide and somatostatin in acute and chronic pancreatitis. Digestion. 1999;60 Suppl 2:23-31.

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
1

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Octreotide

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C49H66N10O10S2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64)/t28-,29?,34-,36+,37+,38-,39-,40+,41+,42+/m1/s1

# InChI_Key:
InChIKey=DEQANNDTNATYII-RRCPSWKPSA-N

# Indication:
For treatment of acromegaly and reduction of side effects from cancer chemotherapy

# KEGG_Compound_ID:
C07306

# KEGG_Drug_ID:
D00442

# LIMS_Drug_ID:
104

# Mechanism_Of_Action:
Octreotide binds to somatostatin receptors. These receptors are coupled via pertussis toxin sensitive G proteins which lead to inhibition of adenylyl cyclase. Octreotide binding to these receptors also stimulates phosphotyrosine phosphatase and activation of the Na(+)/H(+) exchanger via pertussis toxin insensitive G proteins.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
1019.239

# Molecular_Weight_Mono:
1018.440479762

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA450678

# Pharmacology:
Octreotide exerts pharmacologic actions similar to the natural hormone, somatostatin. It is an even more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Like somatostatin, it also suppresses leuteinizing hormone (LH) response to GnRH, decreases splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, and pancreatic polypeptide. Octreotide has been used to treat the symptoms associated with metastatic carcinoid tumors (flushing and diarrhea), and Vasoactive Intestinal Peptide (VIP) secreting adenomas (watery diarrhea). Octreotide substantially reduces and in many cases can normalize growth hormone and/or IGF-1 (somatomedin C) levels in patients with acromegaly.

# Predicted_LogP_Hydrophobicity:
0.42

# Predicted_LogS:
-4.9

# Predicted_Water_Solubility:
1.22e-02 g/l

# Primary_Accession_No:
DB00104

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/cgi/generic/octreotide.htm

# Salts:
Octreotide acetate

# Secondary_Accession_No:
BIOD00088
BTD00088

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](N)CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(=O)N1

# State:
liquid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Octreotida [Spanish]
Octreotidum [Latin]
Octrotide

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:19:06 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Octreotide

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
MPO

# Phase_1_Metabolizing_Enzyme_1_ID:
1757

# Phase_1_Metabolizing_Enzyme_1_Name:
Myeloperoxidase

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Myeloperoxidase precursor
MGVPFFSSLRCMVDLGPCWAGGLTAEMKLLLALAGLLAILATPQPSEGAAPAVLGEVDTS
LVLSSMEEAKQLVDKAYKERRESIKQRLRSGSASPMELLSYFKQPVAATRTAVRAADYLH
VALDLLERKLRSLWRRPFNVTDVLTPAQLNVLSKSSGCAYQDVGVTCPEQDKYRTITGMC
NNRRSPTLGASNRAFVRWLPAEYEDGFSLPYGWTPGVKRNGFPVALARAVSNEIVRFPTD
QLTPDQERSLMFMQWGQLLDHDLDFTPEPAARASFVTGVNCETSCVQQPPCFPLKIPPND
PRIKNQADCIPFFRSCPACPGSNITIRNQINALTSFVDASMVYGSEEPLARNLRNMSNQL
GLLAVNQRFQDNGRALLPFDNLHDDPCLLTNRSARIPCFLAGDTRSSEMPELTSMHTLLL
REHNRLATELKSLNPRWDGERLYQEARKIVGAMVQIITYRDYLPLVLGPTAMRKYLPTYR
SYNDSVDPRIANVFTNAFRYGHTLIQPFMFRLDNRYQPMEPNPRVPLSRVFFASWRVVLE
GGIDPILRGLMATPAKLNRQNQIAVDEIRERLFEQVMRIGLDLPALNMQRSRDHGLPGYN
AWRRFCGLPQPETVGQLGTVLRNLKLARKLMEQYGTPNNIDIWMGGVSEPLKRKGRVGPL
LACIIGTQFRKLRDGDRFWWENEGVFSMQQRQALAQISLPRIICDNTGITTVSKNNIFMS
NSYPRDFVNCSTLPALNLASWREAS

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P05164

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
15103227	Matrone C, Pivonello R, Colao A, Cappabianca P, Cavallo LM, Del Basso De Caro ML, Taylor JE, Culler MD, Lombardi G, Di Renzo GF, Annunziato L: Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs. Neuroendocrinology. 2004 Mar;79(3):142-8. Epub 2004 Apr 16.
16223973	Ruan W, Fahlbusch F, Clemmons DR, Monaco ME, Walden PD, Silva AP, Schmid HA, Kleinberg DL: SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3? Mol Endocrinol. 2006 Feb;20(2):426-36. Epub 2005 Oct 13.
16438887	Wang ZZ, Qu W, Wang F, Li Y, Wang SK, Wang JQ: [Expression of somatostatin receptor reporter gene and its correlation with targeted imaging in vivo for detection of pancreas carcinoma] Zhonghua Zhong Liu Za Zhi. 2005 Nov;27(11):663-6.
16625841	Jaquet P, Gunz G, Saveanu A, Barlier A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Culler MD: BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J Endocrinol Invest. 2005;28(11 Suppl International):21-7.
16625842	Schmid HA, Silva AP: Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats. J Endocrinol Invest. 2005;28(11 Suppl International):28-35.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
SSTR1

# Drug_Target_1_GenBank_ID_Gene:
M81829

# Drug_Target_1_GenBank_ID_Protein:
307434

# Drug_Target_1_GeneCard_ID:
SSTR1

# Drug_Target_1_Gene_Name:
SSTR1

# Drug_Target_1_Gene_Sequence:
>1176 bp
ATGTTCCCCAATGGCACCGCCTCCTCTCCTTCCTCCTCTCCTAGCCCCAGCCCGGGCAGC
TGCGGCGAAGGCGGCGGCAGCAGGGGCCCCGGGGCCGGCGCTGCGGACGGCATGGAGGAG
CCAGGGCGAAATGCGTCCCAGAACGGGACCTTGAGCGAGGGCCAGGGCAGCGCCATCCTG
ATCTCTTTCATCTACTCCGTGGTGTGCCTGGTGGGGCTGTGTGGGAACTCTATGGTCATC
TACGTGATCCTGCGCTATGCCAAGATGAAGACGGCCACCAACATCTACATCCTAAATCTG
GCCATTGCTGATGAGCTGCTCATGCTCAGCGTGCCCTTCCTAGTCACCTCCACGTTGTTG
CGCCACTGGCCCTTCGGTGCGCTGCTCTGCCGCCTCGTGCTCAGCGTGGACGCGGTCAAC
ATGTTCACCAGCATCTACTGTCTGACTGTGCTCAGCGTGGACCGCTACGTGGCCGTGGTG
CATCCCATCAAGGCGGCCCGCTACCGCCGGCCCACCGTGGCCAAGGTAGTAAACCTGGGC
GTGTGGGTGCTATCGCTGCTCGTCATCCTGCCCATCGTGGTCTTCTCTCGCACCGCGGCC
AACAGCGACGGCACGGTGGCTTGCAACATGCTCATGCCAGAGCCCGCTCAACGCTGGCTG
GTGGGCTTCGTGTTGTACACATTTCTCATGGGCTTCCTGCTGCCCGTGGGGGCTATCTGC
CTGTGCTACGTGCTCATCATTGCTAAGATGCGCATGGTGGCCCTCAAGGCCGGCTGGCAG
CAGCGCAAGCGCTCGGAGCGCAAGATCACCTTAATGGTGATGATGGTGGTGATGGTGTTT
GTCATCTGCTGGATGCCTTTCTACGTGGTGCAGCTGGTTAACGTGTTTGCTGAGCAGGAC
GACGCCACGGTGAGTCAGCTGTCGGTCATCCTCGGCTATGCCAACAGCTGCGCCAACCCC
ATCCTCTATGGCTTTCTCTCAGACAACTTCAAGCGCTCTTTCCAACGCATCCTATGCCTC
AGCTGGATGGACAACGCCGCGGAGGAGCCGGTTGACTATTACGCCACCGCGCTCAAGAGC
CGTGCCTACAGTGTGGAAGACTTCCAACCTGAGAACCTGGAGTCCGGCGGCGTCTTCCGT
AATGGCACCTGCACGTCCCGGATCACGACGCTCTGA

# Drug_Target_1_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_1_General_References:
10734105	Schwarzler A, Kreienkamp HJ, Richter D: Interaction of the somatostatin receptor subtype 1 with the human homolog of the Shk1 kinase-binding protein from yeast. J Biol Chem. 2000 Mar 31;275(13):9557-62.
1346068	Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S: Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):251-5.

# Drug_Target_1_HGNC_ID:
HGNC:11330

# Drug_Target_1_HPRD_ID:
01673

# Drug_Target_1_ID:
503

# Drug_Target_1_Locus:
14q13

# Drug_Target_1_Molecular_Weight:
42687

# Drug_Target_1_Name:
Somatostatin receptor type 1

# Drug_Target_1_Number_of_Residues:
391

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_1_Protein_Sequence:
>Somatostatin receptor type 1
MFPNGTASSPSSSPSPSPGSCGEGGGSRGPGAGAADGMEEPGRNASQNGTLSEGQGSAIL
ISFIYSVVCLVGLCGNSMVIYVILRYAKMKTATNIYILNLAIADELLMLSVPFLVTSTLL
RHWPFGALLCRLVLSVDAVNMFTSIYCLTVLSVDRYVAVVHPIKAARYRRPTVAKVVNLG
VWVLSLLVILPIVVFSRTAANSDGTVACNMLMPEPAQRWLVGFVLYTFLMGFLLPVGAIC
LCYVLIIAKMRMVALKAGWQQRKRSERKITLMVMMVVMVFVICWMPFYVVQLVNVFAEQD
DATVSQLSVILGYANSCANPILYGFLSDNFKRSFQRILCLSWMDNAAEEPVDYYATALKS
RAYSVEDFQPENLESGGVFRNGTCTSRITTL

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Receptor for somatostatin with higher affinity for somatostatin-14 than -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase. In addition it stimulates phosphotyrosine phosphatase and Na(+)/H(+) exchanger via pertussis toxin insensitive G proteins

# Drug_Target_1_SwissProt_ID:
P30872

# Drug_Target_1_SwissProt_Name:
SSR1_HUMAN

# Drug_Target_1_Synonyms:
SRIF-2
SS1R

# Drug_Target_1_Theoretical_pI:
8.40

# Drug_Target_1_Transmembrane_Regions:
57-84
95-120
132-153
176-196
220-244
271-296
304-327

# Drug_Target_2_Cellular_Location:
Membrane

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
16086874	Xie Y, Tang CW, Wang CH: [Effect of HBV X gene transfection on octreotide-inhibited growth of hepatocellular carcinoma cell line HepG2] Ai Zheng. 2005 Aug;24(8):965-9.
16438887	Wang ZZ, Qu W, Wang F, Li Y, Wang SK, Wang JQ: [Expression of somatostatin receptor reporter gene and its correlation with targeted imaging in vivo for detection of pancreas carcinoma] Zhonghua Zhong Liu Za Zhi. 2005 Nov;27(11):663-6.
16625841	Jaquet P, Gunz G, Saveanu A, Barlier A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Culler MD: BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J Endocrinol Invest. 2005;28(11 Suppl International):21-7.
16625842	Schmid HA, Silva AP: Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats. J Endocrinol Invest. 2005;28(11 Suppl International):28-35.
16809928	Bronstein MD: Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome. Front Horm Res. 2006;35:129-34.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
SSTR5

# Drug_Target_2_GenBank_ID_Gene:
L14865

# Drug_Target_2_GenBank_ID_Protein:
431095

# Drug_Target_2_GeneCard_ID:
SSTR5

# Drug_Target_2_Gene_Name:
SSTR5

# Drug_Target_2_Gene_Sequence:
>1092 bp
ATGGAGCCCCTGTTCCCAGCCTCCACGCCCAGCTGGAACGCCTCCTCCCCGGGGGCTGCC
TCTGGAGGCGGTGACAACAGGACGCTGGTGGGGCCGGCGCCCTCGGCAGGGGCCCGGGCG
GTGCTGGTGCCCGTGCTGTACCTGCTGGTGTGTGCGGCCGGGCTGGGCGGGAACACGCTG
GTCATCTACGTGGTGCTGCGGTTCGCCAAGATGAAGACCGTCACCAACATCTACATTCTC
AACCTGGCAGTGGCCGACGTCCTGTACATGCTGGGGCTGCCTTTCCTGGCCACGCAGAAC
GCCGCGTCCTTCTGGCCCTTCGGCCCCGTCCTGTGCCGCCTGGTCATGACGCTGGACGGC
GTCAACCAGTTCACCAGTGTCTTCTGCCTGACAGTCATGAGCGTGGACCGCTACCTGGCA
GTGGTGCACCCGCTGAGCTCGGCCCGCTGGCGCCGCCCGCGTGTGGCCAAGCTGGCGAGC
GCCGCCGCCTGGGTCCTGTCTCTGTGCATGTCGCTGCCGCTCTTGGTGTTCGCGGACGTG
CAGGAGGGCGGTACCTGCAACGCCAGCTGGCCGGAGCCCGTGGGGCTGTGGGGCGCCGTC
TTCATCATCTACACGGCCGTGCTGGGCTTCTTCGCGCCGCTGCTGGTCATCTGCCTGTGC
TACCTGCTCATCGTGGTGAAGGTGAGGGCGGCGGGCGTGCGCGTGGGCTGCGTGCGGCGG
CGCTCGGAGCGGAAGGTGACGCGCATGGTGTTGGTGGTGGTGCTGGTGTTTGCGGGATGT
TGGCTGCCCTTCTTCACCGTCAACATCGTCAACCTGGCGGTTGCGCTGCCCCAGGAGCCC
GCCTCCGCCGGCCTCTACTTCTTCGTGGTCATCCTCTCCTACGCCAACAGCTGTGCCAAC
CCCGTCCTCTACGGCTTCCTCTCGGACAACTTCCGCCAGAGCTTCCAGAAGGTTCTGTGC
CTCCGCAAGGGCTCTGGTGCCAAGGACGCTGACGCCACGGAGCCGCGTCCAGACAGGATC
CGGCAGCAGCAGGAGGCCACGCGCCCGCGCACCGCCGCAGCCAACGGGCTTATGCAGACC
AGCAAGCTGTGA

# Drug_Target_2_General_Function:
Not Available

# Drug_Target_2_General_References:
11157797	Daniels RJ, Peden JF, Lloyd C, Horsley SW, Clark K, Tufarelli C, Kearney L, Buckle VJ, Doggett NA, Flint J, Higgs DR: Sequence, structure and pathology of the fully annotated terminal 2 Mb of the short arm of human chromosome 16. Hum Mol Genet. 2001 Feb 15;10(4):339-52.
7908405	Panetta R, Greenwood MT, Warszynska A, Demchyshyn LL, Day R, Niznik HB, Srikant CB, Patel YC: Molecular cloning, functional characterization, and chromosomal localization of a human somatostatin receptor (somatostatin receptor type 5) with preferential affinity for somatostatin-28. Mol Pharmacol. 1994 Mar;45(3):417-27.
8078491	O'Carroll AM, Raynor K, Lolait SJ, Reisine T: Characterization of cloned human somatostatin receptor SSTR5. Mol Pharmacol. 1994 Aug;46(2):291-8.
8373420	Yamada Y, Kagimoto S, Kubota A, Yasuda K, Masuda K, Someya Y, Ihara Y, Li Q, Imura H, Seino S, et al.: Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype. Biochem Biophys Res Commun. 1993 Sep 15;195(2):844-52.

# Drug_Target_2_HGNC_ID:
HGNC:11334

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
3872

# Drug_Target_2_Locus:
16p13.3

# Drug_Target_2_Molecular_Weight:
39203

# Drug_Target_2_Name:
Somatostatin receptor type 5

# Drug_Target_2_Number_of_Residues:
364

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_2_Protein_Sequence:
>Somatostatin receptor type 5
MEPLFPASTPSWNASSPGAASGGGDNRTLVGPAPSAGARAVLVPVLYLLVCAAGLGGNTL
VIYVVLRFAKMKTVTNIYILNLAVADVLYMLGLPFLATQNAASFWPFGPVLCRLVMTLDG
VNQFTSVFCLTVMSVDRYLAVVHPLSSARWRRPRVAKLASAAAWVLSLCMSLPLLVFADV
QEGGTCNASWPEPVGLWGAVFIIYTAVLGFFAPLLVICLCYLLIVVKVRAAGVRVGCVRR
RSERKVTRMVLVVVLVFAGCWLPFFTVNIVNLAVALPQEPASAGLYFFVVILSYANSCAN
PVLYGFLSDNFRQSFQKVLCLRKGSGAKDADATEPRPDRIRQQQEATPPAHRAAANGLMQ
TSKL

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Receptor for somatostatin 28 and to a lesser extent for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase

# Drug_Target_2_SwissProt_ID:
P35346

# Drug_Target_2_SwissProt_Name:
SSR5_HUMAN

# Drug_Target_2_Synonyms:
SS5R

# Drug_Target_2_Theoretical_pI:
9.72

# Drug_Target_2_Transmembrane_Regions:
39-66
77-101
114-135
158-178
198-222
248-273
284-308

# Drug_Target_3_Cellular_Location:
Cell membrane

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
19537708	Yim CB, Boerman OC, de Visser M, de Jong M, Dechesne AC, Rijkers DT, Liskamp RM: Versatile conjugation of octreotide to dendrimers by cycloaddition ("click") chemistry to yield high-affinity multivalent cyclic Peptide dendrimers. Bioconjug Chem. 2009 Jul;20(7):1323-31.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
SSTR2

# Drug_Target_3_GenBank_ID_Gene:
BC095495

# Drug_Target_3_GenBank_ID_Protein:
Not Available

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
SSTR2

# Drug_Target_3_Gene_Sequence:
Not Available

# Drug_Target_3_General_Function:
Not Available

# Drug_Target_3_General_References:
10551867	Zitzer H, Honck HH, Bachner D, Richter D, Kreienkamp HJ: Somatostatin receptor interacting protein defines a novel family of multidomain proteins present in human and rodent brain. J Biol Chem. 1999 Nov 12;274(46):32997-3001.
10619399	Petersenn S, Rasch AC, Presch S, Beil FU, Schulte HM: Genomic structure and transcriptional regulation of the human somatostatin receptor type 2. Mol Cell Endocrinol. 1999 Nov 25;157(1-2):75-85.
1346068	Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S: Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):251-5.
8386508	Patel YC, Greenwood M, Kent G, Panetta R, Srikant CB: Multiple gene transcripts of the somatostatin receptor SSTR2: tissue selective distribution and cAMP regulation. Biochem Biophys Res Commun. 1993 Apr 15;192(1):288-94.

# Drug_Target_3_HGNC_ID:
HGNC:11331

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
6008

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
41333

# Drug_Target_3_Name:
Somatostatin receptor type 2

# Drug_Target_3_Number_of_Residues:
369

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_3_Protein_Sequence:
>Somatostatin receptor type 2
MDMADEPLNGSHTWLSIPFDLNGSVVSTNTSNQTEPYYDLTSNAVLTFIYFVVCIIGLCG
NTLVIYVILRYAKMKTITNIYILNLAIADELFMLGLPFLAMQVALVHWPFGKAICRVVMT
VDGINQFTSIFCLTVMSIDRYLAVVHPIKSAKWRRPRTAKMITMAVWGVSLLVILPIMIY
AGLRSNQWGRSSCTINWPGESGAWYTGFIIYTFILGFLVPLTIICLCYLFIIIKVKSSGI
RVGSSKRKKSEKKVTRMVSIVVAVFIFCWLPFYIFNVSSVSMAISPTPALKGMFDFVVVL
TYANSCANPILYAFLSDNFKKSFQNVLCLVKVSGTDDGERSDSKQDKSRLNETTETQRTL
LNGDLQTSI

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Receptor for somatostatins-14 and -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase. In addition it stimulates phosphotyrosine phosphatase and PLC via pertussis toxin insensitive as well as sensitive G proteins. In RIN-5F cells, this receptor inhibits calcium entry by suppressing voltage dependent calcium-channels

# Drug_Target_3_SwissProt_ID:
P30874

# Drug_Target_3_SwissProt_Name:
SSR2_HUMAN

# Drug_Target_3_Synonyms:
SRIF-1
SS2R

# Drug_Target_3_Theoretical_pI:
9.18

# Drug_Target_3_Transmembrane_Regions:
44-67
79-103
119-138
162-181
208-229
254-278
289-303

#END_DRUGCARD DB00104
